Division of Endocrinology and Metabolism, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, Sichuan, China.
College of Life Sciences, Sichuan University, Chengdu, 610041, Sichuan, China.
Mol Cancer. 2020 Sep 24;19(1):145. doi: 10.1186/s12943-020-01258-7.
As a point of convergence for numerous oncogenic signaling pathways, signal transducer and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune response. STAT3 is broadly hyperactivated both in cancer and non-cancerous cells within the tumor ecosystem and plays important roles in inhibiting the expression of crucial immune activation regulators and promoting the production of immunosuppressive factors. Therefore, targeting the STAT3 signaling pathway has emerged as a promising therapeutic strategy for numerous cancers. In this review, we outline the importance of STAT3 signaling pathway in tumorigenesis and its immune regulation, and highlight the current status for the development of STAT3-targeting therapeutic approaches. We also summarize and discuss recent advances in STAT3-based combination immunotherapy in detail. These endeavors provide new insights into the translational application of STAT3 in cancer and may contribute to the promotion of more effective treatments toward malignancies.
作为众多致癌信号通路的汇聚点，信号转导子和转录激活子 3（STAT3）在调节抗肿瘤免疫反应中起着核心作用。STAT3 在肿瘤生态系统中的癌症和非癌细胞中广泛被过度激活，在抑制关键免疫激活调节剂的表达和促进免疫抑制因子的产生方面发挥着重要作用。因此，靶向 STAT3 信号通路已成为治疗多种癌症的一种有前途的治疗策略。在这篇综述中，我们概述了 STAT3 信号通路在肿瘤发生及其免疫调节中的重要性，并强调了目前开发 STAT3 靶向治疗方法的现状。我们还详细总结和讨论了基于 STAT3 的联合免疫疗法的最新进展。这些努力为 STAT3 在癌症中的转化应用提供了新的见解，并可能有助于促进针对恶性肿瘤的更有效的治疗方法。
Zotero 插件
